Docetaxel

Generic Name: Docetaxel

Brand Names: Taxotere, Docetaxel Accord, Docetaxel Kabi

Drug Type: Small Molecule

Chemical Formula: C_₄₃H_₅₃NO_₁₄

CAS Number: 114977-28-5

Unique Ingredient Identifier: 699121PHCA

Background: Docetaxel is a clinically well established anti-mitotic chemotherapy medication used for the treatment of different types of cancer, including breast, ovarian, and non-small cell lung cancer. Docetaxel is a complex diterpenoid molecule and a semisynthetic analogue of paclitaxel. Docetaxel reversibly binds to microtubulin with high affinity in a 1:1 stoichiom...

Indication: Docetaxel is indicated as a single agent for the treatment of locally advanced or metastatic breast cancer after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC. It is also indicated as a single agent for locally advanced or metastatic non-small cell lung cancer (NSCLC) after platinum therapy...

Associated Conditions: Esophageal Cancer, Ewing's Sarcoma, Locally Advanced Breast Cancer (LABC), Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Node Positive Breast Cancer, Ovarian Cancer Metastatic, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Advanced untreated gastric adenocarcinoma, Locally advanced Squamous cell carcinoma of head and neck, Locally advanced untreated non small cell lung cancer, Metastatic untreated non small cell lung cancer, Refractory, locally advanced Non small cell lung cancer, Refractory, metastatic Non small cell lung cancer, Refractory, metastatic hormone-refractory Prostate cancer

Associated Therapies: -

Clinical Trials

Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer

Phase 2

Terminated

Conditions: Ovarian Cancer
Primary Peritoneal Cavity Cancer

First Posted Date: 2003-06-25

Last Posted Date: 2013-04-11

Lead Sponsor: Gynecologic Oncology Group

Registration Number: NCT00004037

Locations: 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States

and more 64 locations

Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer

Phase 2

Completed

Conditions: Adenocarcinoma of the Prostate
Hormone-resistant Prostate Cancer
Recurrent Prostate Cancer
Stage IV Prostate Cancer

Interventions: Drug: estramustine phosphate sodium
Drug: docetaxel
Biological: bevacizumab
Other: laboratory biomarker analysis

First Posted Date: 2003-06-10

Last Posted Date: 2013-06-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 72

Registration Number: NCT00016107

Locations: 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States

S0220: Chemoradiotherapy Followed By Surgery and Docetaxel in Treating Patients With Pancoast Tumors

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: cisplatin
Drug: docetaxel
Drug: etoposide
Procedure: conventional surgery
Radiation: radiation therapy

First Posted Date: 2003-06-06

Last Posted Date: 2013-11-25

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 46

Registration Number: NCT00062439

Locations: 🇺🇸
Cardinal Bernardin Cancer Center at Loyola University Medical Center, Maywood, Illinois, United States
🇺🇸
Holland Community Hospital, Holland, Michigan, United States
🇺🇸
Providence Cancer Institute at Providence Hospital - Southfield Campus, Southfield, Michigan, United States

and more 150 locations

Neoadjuvant Chemoradiotherapy With or Without Gefitinib in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer

First Posted Date: 2003-06-06

Last Posted Date: 2015-10-08

Lead Sponsor: University of Alabama at Birmingham

Registration Number: NCT00062270

Locations: 🇺🇸
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States

Docetaxel and Cisplatin in Treating Patients With Untreated Stage IIIA Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

First Posted Date: 2003-05-21

Last Posted Date: 2012-07-18

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 47

Registration Number: NCT00005868

Locations: 🇳🇱
Leiden University Medical Center, Leiden, Netherlands
🇮🇹
Istituto Nazionale per la Ricerca sul Cancro, Genoa (Genova), Italy
🇳🇱
Groot Ziekengasthuis 's-Hertogenbosch, 's-Hertogenbosch, Netherlands

and more 20 locations

Combination Chemotherapy in Treating Patients With Stage IV Locally Advanced or Metastatic Bladder Cancer

Phase 2

Completed

Conditions: Bladder Cancer

Interventions: Drug: cisplatin
Drug: docetaxel
Drug: gemcitabine hydrochloride
Drug: methotrexate

First Posted Date: 2003-05-16

Last Posted Date: 2013-09-05

Lead Sponsor: University of Chicago

Target Recruit Count: 6

Registration Number: NCT00005086

Locations: 🇺🇸
Louis A. Weiss Memorial Hospital, Chicago, Illinois, United States
🇺🇸
Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States

and more 1 locations

Docetaxel in Treating Older Patients With Metastatic Breast, Lung, or Prostate Cancer

Phase 2

Completed

Conditions: Breast Cancer
Lung Cancer
Prostate Cancer

First Posted Date: 2003-05-07

Last Posted Date: 2013-01-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00059943

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Docetaxel and Oxaliplatin in Treating Patients With Metastatic or Recurrent Solid Tumor

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2003-04-18

Last Posted Date: 2010-01-13

Lead Sponsor: City of Hope Medical Center

Registration Number: NCT00004243

Locations: 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Beckman Research Institute, City of Hope, Los Angeles, California, United States
🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States

S0224, Docetaxel in Treating Patients With Locally Advanced or Metastatic Penile Cancer (TERMINATED)

Phase 2

Terminated

Conditions: Penile Cancer

First Posted Date: 2003-04-09

Last Posted Date: 2018-06-28

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 1

Registration Number: NCT00058448

Locations: 🇺🇸
Kalispell Regional Medical Center, Kalispell, Montana, United States
🇺🇸
Riverside Methodist Hospital Cancer Care, Columbus, Ohio, United States
🇺🇸
Rose Ramer Cancer Clinic at Anderson Area Medical Center, Anderson, South Carolina, United States

and more 46 locations

Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors

Phase 1

Completed

Conditions: Stage IV Prostate Cancer
Unspecified Adult Solid Tumor, Protocol Specific
Recurrent Prostate Cancer

Interventions: Drug: tanespimycin
Drug: docetaxel

First Posted Date: 2003-04-09

Last Posted Date: 2014-06-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 80

Registration Number: NCT00058253

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy